Abstract:Objective: To evaluate the efficacy of oral vinorelbine plus cisplatin and Ⅳ vinorelbine plus cisplatin in advanced non-small-cell lung cancer (NSCLC), and to appraise the progression-free survival, toxicity, and the safety of both therapeutic applications. Methods: Patients who met the inclusion criteria were randomly (1:1) assigned to the experimental group with oral vinorelbine plus cisplatin (arm A) or the control group with intravenous (Ⅳ) vinorelbine plus cisplatin (arm B). Patients in both the groups were treated with the two therapeutic regimens administered once every 3 weeks. In the first course of treatment, the oral vinorelbine was administrated at a dose of 60 mg/m~2 on day 1 and 8, while the IV vinorelbine was administrated at a dose of 25 mg/m~2 on day 1 and 8. In both groups, cisplatin was administrated at the dose of 80 mg/m~2 on day 1. In the second course of treatment, the dose of oral vinorelbine was raised up to 80 mg/m2 and the Ⅳ vinorelbine was raised to 30 mg/m~2 for the following cycles, if no severe hematological toxicity was found in these patients. Tumor response rate was appraised according to RECIST criteria, and the toxicity grading was appraised based on NCI-CTC Version 2.0. Results: A total of 39 eligible subjects were enrolled in the Cancer Center of Sun Yat-Sen University, with 19 in the experimental group and 20 controls. Characteristics including gender, age, performance status, clinical stage, histo-types and smoking status were balanced in the patients of both groups. Data were analyzed in the intention-to-treat manner. The objective remission rate was 31.6% and 42.1% (P=0.737), and the clinical benefit rate was 52.6% and 68.4% (P=0.508) in arm A and B, respectively. The median progression-free survival was 85 and 115 days, respectively, in arm A and B (P=0.705). Toxic reactions in both groups included neutropenia, anemia, gastrointestinal reactions and phlebitis. Grade-2 phlebitis notably increased in arm B (68.4% vs. 21.0%), with a statistically significant difference between the two groups (P=0.008). No significant differences were found in the comparison of other adverse effects and grade- Ⅲ～Ⅳ un- toward reactions between the subjects of the 2 groups. Conclusion: The efficacy of oral vinorelbine plus cisplatin regimen is similar to that of the Ⅳ vinorelbine and cisplatin regimen in the cases with advanced non-small-cell lung cancer (NSCLC). The hematological toxicity and non-hematological toxicity were lower in the experimental group than in the controls. A larger -scale phase-Ⅲ clinical study is needed to further evaluate the efficacy and toxicity of oral vinorelbine in Asian patients.

First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer

First-line chemotherapy of vinorelbine/cisplatin (NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC): P2-327

A Comparative Study for Vinorelbine with Cisplatin Plus Mitomycin and Vinorelbine with Cisplatin in Advanced Non-Small-cell Lung Cancer

A Phase Ⅱ Clinical Trial of Celecoxib Combined with Platinum-Based Chemotherapy in the Treatment of Patients with Advanced NSCLC As First-Line Treatment

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Compare and Evaluate Two Combination Regimens of Vinorelbine Plus Gemcitabine and Cisplatin Pins Vinorelbine for Treatment of Patients with Advanced Non-Small-cell Lung Cancer

Vinorelbine based combination chemotherapy in advanced non-small cell lung cancer

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

First-line Chemotherapy of Docetaxel/Cisplatin for Advanced Non-small Cell Lung Cancer

Chemotherapy Based on Regimes of Gemcitabine Plus Cisplatin or Vinorelbine Plus Cisplatin in Patients with Advanced NSCLC

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

[Comparison of Cisplatin Combined with Gemcitabine Versus Cisplatin Combined with Vinorelbine Regimen for Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

[The Efficacy of Vinorelbine Plus Cisplatin in the Treatment of 48 Cases of Advanced Non-Small Cell Lung Cancer].

Vinorelbine Plus Cisplatin in the Treatment of 38 Cases with Advanced Non-Small Cell Lung Cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

A Randomized Trial Comparing Oxaliplatin Plus Vinorelbine Versus Cisplatin Plus Vinorelbine for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

A Clinical Study on Efficacy and Toxicity of NP in Contrast to the MNP Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

Clinical Efficacy of Toremifene Combined with Second Line Drugs Novelbine/cisplatin on Advanced Non-Small Cell Lung Cancer

Effect of Oral Vinorelbine plus Cisplatin in Unresectable Localized or Metastatic Non-Small Cell Lung Cancer (NSCLC): A Report of Stage-Ⅱ Clinical Research

[Vinorelbine Plus Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer Previously Treated with Taxane-Based Chemotherapy].

Comparison of Short-term Efficacy between the NP and GP Regimens in the Treatment of Advanced Non-small-cell Lung Canaer